Revolution Medicines (RVMD) has begun treating patients in RASolute 303, a global Phase 3 trial of its RAS inhibitor daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma, spotlighting a key late stage pipeline milestone.
See our latest analysis for Revolution Medicines.
That trial milestone comes after a strong run in the stock, with a 90 day share price return of 26.54% and a one year total shareholder return of 216.48%, pointing to strong momentum around the story.
If this kind of oncology progress has your attention, it may be a good time to widen your watchlist and check out 36 healthcare AI stocks
With Revolution Medicines now trading at $99.12, a value score of 2 and modelled intrinsic and analyst targets implying room above the current price, investors face a key question: is there still upside here or is the market already pricing in future growth?
Most Popular Narrative: 25.9% Undervalued
With Revolution Medicines at $99.12 and the most followed narrative pointing to a fair value of $133.70, the gap between price and expectations is clear and rooted in ambitious oncology assumptions.
The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.
Want to see what is baked into that optimism? The narrative leans on aggressive revenue scaling, meaningful margin expansion and a future profit multiple that assumes strong execution across the RAS pipeline.
Result: Fair Value of $133.70 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upbeat narrative still hinges on a costly RAS-focused pipeline and heavy 2026 operating expenses of US$1.6b to US$1.7b if trial setbacks emerge.
Find out about the key risks to this Revolution Medicines narrative.
Another Angle: Rich On P/B Despite Cash Flow Upside
The DCF work points to a very large gap to fair value, with Revolution Medicines trading at 80.8% below our cash flow estimate and below our future cash flow value of $515.55. Yet on P/B, the stock trades at 12x versus 2.2x for the US Biotechs industry and 8.2x for peers. That kind of premium can reward you if the pipeline plays out, but it also raises the question of how much margin for error is really left in the price.
Before leaning too hard on any one approach, it can help to see exactly how the cash flow view is built in the SWS DCF model, and where your own assumptions might differ, Look into how the SWS DCF model arrives at its fair value.
Next Steps
With sentiment split between the pipeline opportunity and the execution risks, it makes sense to look at the numbers yourself and move quickly to your own conclusion by weighing 2 key rewards and 2 important warning signs.
Looking for more investment ideas?
If Revolution Medicines has sharpened your focus, do not stop here. Use the Simply Wall St Screener to find other opportunities that might suit your approach.
- Target potential mispricing by scanning 58 high quality undervalued stocks that pair quality fundamentals with room between their current prices and underlying metrics.
- Strengthen your income focus by reviewing 13 dividend fortresses that combine higher yields with an emphasis on resilience.
- Prioritise sturdier balance sheets by filtering for solid balance sheet and fundamentals stocks screener (40 results) that can support operations through tougher periods.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com